ALOXI 0.25 mg/ 5 ml Solution For Injection
ALOXI 0.25 mg/5 ml Solution For Injection
ALOXI 0.25 mg/5 ml Solution For Injection is a highly effective medication designed to prevent nausea and vomiting associated with cancer chemotherapy.
As a 5-HT3 receptor antagonist, Aloxi works by blocking serotonin, a natural substance in the body that can cause nausea and vomiting.
It is typically administered intravenously by a healthcare professional before chemotherapy sessions.
This product is a critical component of supportive care for patients undergoing emetogenic chemotherapy, aiming to improve their quality of life by minimizing distressing side effects.
Always consult your healthcare provider for appropriate use and dosage.
Benefits of Use
- Highly effective in preventing both acute and delayed chemotherapy-induced nausea and vomiting (CINV).
- Provides sustained antiemetic control for up to 48 hours following a single dose.
- Significantly improves patient comfort and reduces the burden of chemotherapy side effects.
- Well-tolerated profile when used as directed by a healthcare professional.
How to Use
ALOXI 0.25 mg/5 ml Solution For Injection must be administered by a qualified healthcare professional. The typical administration steps are as follows:
- Confirm the correct dosage and patient identity.
- Administer ALOXI as a single intravenous (IV) dose approximately 30 minutes prior to the start of chemotherapy.
- The injection should be administered undiluted over a period of 30 seconds.
- Ensure proper sterile technique throughout the administration process.
- Monitor the patient for any immediate reactions or adverse effects post-administration.
Caution & Warnings
- Do not use ALOXI in patients with known hypersensitivity to palonosetron or any of its components.
- This medication should only be administered by a healthcare professional.
- Monitor for signs of serotonin syndrome, especially when co-administered with other serotonergic drugs (e.g., SSRIs, SNRIs).
- Caution should be exercised in patients with cardiac abnormalities or those receiving cardiotoxic chemotherapy.
- Report any serious side effects or allergic reactions to your healthcare provider immediately.
- Keep out of reach of children.
Ingredients
- Active Ingredient: Palonosetron Hydrochloride (equivalent to 0.25 mg Palonosetron)
- Inactive Ingredients: Mannitol, Disodium Edetate, Sodium Citrate Dihydrate, Citric Acid Monohydrate, Water for Injection. Sodium Hydroxide and/or Hydrochloric Acid may be used for pH adjustment.
Product Details
- Dosage Form: Solution for Injection
- Strength: 0.25 mg Palonosetron
- Volume: 5 ml per vial
- Manufacturer: Helsinn Healthcare SA
- Therapeutic Class: 5-HT3 Receptor Antagonist (Antiemetic)
| Gtin | 1-5078-17 |
|---|---|
| Recommended Sale Price | 139 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | PALONOSETRON HYDROCHLORIDE |
| SFDA Reg. No | 1-5078-17 |
| IBC | 1-5078-17 |
| Drug Type | Prescription |
| Scientific Name | Palonosetron Hydrochloride |
| Strength | 0.25 |
| Strength Unit | mg |
| Form | Solution For Injection |
| Admin Route | Intravenous |
| Size | 5 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | Single-dose vial |
| Storage conditions | Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze. |
| Refrigerator Storage | No |
